文献速递中毒与环境急症消化、代谢与肾脏急症

对乙酰氨基酚浓度与转氨酶活性乘积在识别超过Rumack-Matthew列线图150 mg/L治疗线的患者中的诊断效用

Diagnostic utility of the paracetamol concentration aminotransferase activity multiplication product in identifying patients exceeding the 150 mg/L treatment line on the Rumack-Matthew nomogram.
PubMed 文献 · Clin Toxicol (Phila) · 2025-12-11
一句话结论回顾性研究显示,对乙酰氨基酚浓度与转氨酶活性乘积可预测血药浓度超过150 mg/L治疗线,最佳截断值1501.6 mg*U/L²,灵敏度84.8%、特异度79.8%。

该研究回顾了泰国Siriraj医院2007年1月至2016年12月收治的934例急性对乙酰氨基酚过量患者,计算血清对乙酰氨基酚浓度(mg/L)与丙氨酸氨基转移酶或天冬氨酸氨基转移酶较高活性(U/L)的乘积,用以识别血药浓度超过Rumack-Matthew列线图150治疗线的病例。结果显示,43.5%(406例)患者浓度超过150治疗线,乘积的ROC曲线下面积为0.874,最佳截断值1501.6 mg*U/L²的灵敏度为84.8%、特异度为79.8%。讨论部分显示,150治疗线预测肝毒性的灵敏度为100.0%(95%CI 93.7-100.0%)、特异度为60.2%(95%CI 56.9-63.5%);而乘积截断值1500 mg*U/L²的灵敏度为98.3%(95%CI 90.6-100.0%)、特异度为50.7%(95%CI 47.4-54.1%)。结论认为该乘积能预测血药浓度达到或超过150治疗线。

要点

  • 在934例急性对乙酰氨基酚过量患者中,43.5%(406例)血药浓度超过Rumack-Matthew列线图150治疗线。
  • 乘积(对乙酰氨基酚浓度mg/L×较高转氨酶活性U/L)识别超过150治疗线的ROC曲线下面积为0.874。
  • 最佳截断值1501.6 mg*U/L²的灵敏度84.8%、特异度79.8%,由Youden指数确定。
  • 乘积截断值1500 mg*U/L²预测肝毒性的灵敏度98.3%(95%CI 90.6-100.0%)、特异度50.7%(95%CI 47.4-54.1%)。
  • 150治疗线预测肝毒性的灵敏度100.0%(95%CI 93.7-100.0%)、特异度60.2%(95%CI 56.9-63.5%)。

适用人群与场景

  • 2007年1月至2016年12月收治于泰国曼谷Siriraj医院的急性对乙酰氨基酚过量患者,共934例。

诊断标准与关键阈值

  • 乘积计算:血清对乙酰氨基酚浓度(mg/L)乘以同时采集血样中丙氨酸氨基转移酶或天冬氨酸氨基转移酶较高活性(U/L)。
  • 最佳截断值:1501.6 mg*U/L²,由Youden指数确定,用于识别血药浓度超过Rumack-Matthew列线图150治疗线。

研究设计与关键结果

  • 回顾性研究,纳入934例急性对乙酰氨基酚过量患者,43.5%(406例)血药浓度超过150治疗线。
  • 乘积识别超过150治疗线的ROC曲线下面积为0.874;最佳截断值1501.6 mg*U/L²的灵敏度84.8%、特异度79.8%。
  • 150治疗线预测肝毒性的灵敏度100.0%(95%CI 93.7-100.0%)、特异度60.2%(95%CI 56.9-63.5%)。
  • 乘积截断值1500 mg*U/L²预测肝毒性的灵敏度98.3%(95%CI 90.6-100.0%)、特异度50.7%(95%CI 47.4-54.1%)。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对乙酰氨基酚浓度与转氨酶活性乘积能预测血药浓度达到或超过Rumack-Matthew列线图150治疗线,可在无需精确知道摄入时间的情况下辅助识别超过150治疗线的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Paracetamol poisoning and the associated liver damage can be effectively managed by the timely administration of acetylcysteine. Most treatment protocols depend on the line intersecting 150 mg/L (992 μmol/L) at 4 h on the Rumack-Matthew nomogram (150-treatment line), which requires accurate determination of ingestion time to assess risk. The paracetamol concentration aminotransferase activity multiplication product has emerged as a predictive measure for paracetamol-induced hepatotoxicity in patients receiving acetylcysteine, without necessitating the precise knowledge of ingestion time. This study aims to assess the diagnostic performance of the multiplication product in identifying cases with paracetamol concentrations surpassing the 150-treatment line and to establish an optimal cutoff value for this clinical tool.

METHODS: A retrospective review of acute paracetamol overdoses admitted to Siriraj Hospital in Bangkok, Thailand, from January 2007 to December 2016 was conducted. The multiplication product was calculated by multiplying the serum paracetamol concentration (mg/L) by the higher activity of alanine aminotransferase or aspartate aminotransferase (U/L), both measured from simultaneous blood samples. The diagnostic accuracy of the multiplication product in predicting paracetamol concentrations above the 150-treatment line was evaluated through receiver operating characteristic curve analysis, sensitivity, and specificity. The optimal cutoff value was determined using the Youden index.

RESULTS: Among the 934 patients included, 43.5% (406 cases) presented paracetamol concentrations above the 150-treatment line. The multiplication product had an area under the receiver operating characteristic curve of 0.874. An optimal cutoff of 1,501.6 mg * U/L2 yielded a sensitivity of 84.8% and a specificity of 79.8%.

DISCUSSION: The 150-treatment line on the Rumack-Matthew nomogram demonstrated a sensitivity of 100.0% (95% CI: 93.7 - 100.0%) and a specificity of 60.2% (95% CI: 56.9 - 63.5%) for predicting hepatotoxicity. In comparison, the 1,500 mg * U/L2 cutoff of the paracetamol concentration aminotransferase activity multiplication product showed a sensitivity of 98.3% (95% CI: 90.6 - 100.0%) and a specificity of 50.7% (95% CI: 47.4 - 54.1%).

CONCLUSIONS: The paracetamol concentration aminotransferase activity multiplication product demonstrates predictive ability for serum paracetamol concentrations at or above the 150-treatment line on the Rumack-Matthew nomogram.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Chomchai S, Mekavuthikul P, Phuditshinnapatra J, et al. Diagnostic utility of the paracetamol concentration aminotransferase activity multiplication product in identifying patients exceeding the 150 mg/L treatment line on the Rumack-Matthew nomogram. Clin Toxicol (Phila). 2025. PMID: 41378892. doi:10.1080/15563650.2025.2579132

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。